Models of liver fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ

Journal of Clinical Investigation

Volumn 117, Issue 3, 2007, Pages 539-548

  Iredale, John P ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE; CELL CULTURE; HUMAN; INFLAMMATION; INNATE IMMUNITY; LIVER FIBROSIS; LIVER INJURY; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; T LYMPHOCYTE; TISSUE REPAIR;

ANIMALS; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; INFLAMMATION; LIVER CIRRHOSIS; LIVER CIRRHOSIS, EXPERIMENTAL; LIVER REGENERATION; MODELS, BIOLOGICAL; WOUND HEALING;

EID: 33847363203     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI30542     Document Type: Review

References (120)

1. Friedman, S.L. 2003. Liver fibrosis - from bench to bedside. J. Hepatol. 38(Suppl. 1):S38-S53.
2. Gines, P., Cardenas, A., Arroyo, V., and Rodes, J. 2004. Management of cirrhosis and ascites. N. Engl. J. Med. 350:1646-1654.
3. Iredale, J.P. 2003. Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ. 327:143-147.
4. Fallowfield, J.A., and Iredale, J.P. 2004. Targeted treatments for cirrhosis. Expert Opin. Ther. Targets. 8:423-435.
5. Bataller, R., and Brenner, D.A. 2005. Liver fibrosis. J. Clin. Invest. 115:209-231. doi:10.1172/JCI200524282.
6. Albanis, E., and Friedman, S.L. 2001. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin. Liver Dis. 5:315-334, v-vi.
7. Iredale, J.P. 2001. Hepatic stellate cell behaviour during resolution of liver fibrosis. Semin. Liver Dis. 21:427-436.
8. Friedman, S.L., Roll, F.J., Boyles, J., and Bissell, D.M. 1985. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc. Natl. Acad. Sci. U. S. A. 82:8681-8685.
9. Geerts, A. 2001. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin. Liver Dis. 21:311-335.
10. Friedman, S.L., et al. 1992. Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture. Hepatology. 15:234-243.
11. Pinzani, M., et al. 1992. Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. J. Clin. Invest. 90:642-646.
12. Otto, D.A., and Veech, R.L. 1980. Isolation of a lipocyte-rich fraction from rat liver nonparenchymal cells. Adv. Exp. Med. Biol. 132:509-517.
13. Benyon, R.C., Iredale, J.P., Goddard, S., Winwood, P.J., and Arthur, M.J.P. 1996. Increased expression of tissue inhibitor of metalloproteinases-1 and -2 relative to interstitial collagenase in fibrotic human liver. Gastroenterology. 110:821-831.
14. Wanless, I.R., Nakashima, E., and Sherman, M. 2000. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch. Pathol. Lab. Med. 124:1599-1607.
15. Dufour, J.F., DeLellis, R., and Kaplan, M.M. 1997. Reversibility of hepatic fibrosis is autoimmune hepatitis. Ann. Intern. Med. 127:981-985.
16. Constandinou, C., Henderson, N., and Iredale, J.P. 2005. Modelling liver fibrosis in rodents. Methods Mol. Med. 117:237-250.
17. Tsukamoto, H., Matsuoka, M., and French, S.W. 1990. Experimental models of hepatic fibrosis: a review. Semin. Liver Dis. 10:56-65.
18. Maher, J.J., Bissell, D.M., Friedman, S.L., and Roll, F.J. 1988. Collagen measured in primary cultures of normal rat hepatocytes derives from lipocytes within the monolayer. J. Clin. Invest. 82:450-459.
19. Maher, J.J., and McGuire, R.F. 1990. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J. Clin. Invest. 86:1641-1648.
20. Gabele, E., Brenner, D.A., and Rippe, R.A. 2003. Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. Front. Biosci. 8:D69-D77.
21. Franken, F.H., and Falk, H. 1999. History of hepatology. In Oxford textbook of clinical hepatology. 2nd edition. J. Bircher, J.-P. Benhamou, N. McIntyre, M. Rizetto, and J. Rodes, editors. Oxford University Press. Oxford, United Kingdom. 2067-2076.
22. Anstee, Q.M., and Goldin, R.D. 2006. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 87:1-16.
23. Koteish, A., and Diehl, A.M. 2001. Animal models of steatosis. Semin. Liver Dis. 21:89-104.
24. Kirsch, R., et al. 2003. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J. Gastroenterol. Hepatol. 18:1272-1282.
25. Kulinski, A., Vance, D.E., and Vance, J.E. 2004. A choline-deficient diet in mice inhibits neither the CDP-choine pathway for phosphatidylcholine synthesis in hepatocytes nor apolipoprotein B secretion. J. Biol. Chem. 279:23916-23924.
26. Oliviera, C.P.M.S., et al. 2003. Vitamin C and vitamin E in prevention of nonalcoholic fatty liver disease (NAFLD) in choline deficient diet fed rats. Nutr. J. 2:9-14.
27. Raubenheimer, P.J., Nyirenda, M.J., and Walker, B.R. 2006. A choline deficient diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in mice fed a high fat diet. Diabetes. 55:2015-2020.
28. Vig, P., et al. 2006. The sources of parenchymal regeneration after chronic hepatocellular liver injury in mice. Hepatology. 43:316-324.
29. Chisari, F.V., et al. 1985. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science. 230:1157-1160.
30. Iredale, J.P., et al. 1996. TIMP-1 and interstitial collagenase expression in liver fibrosis; implications for pathogenesis. Hepatology. 24:176-184.
31. Okazaki, I., and Maruyama, K. 1974. Collagenase activity in experimental hepatic fibrosis. Nature. 252:49-50.
32. Montfort, I., and Perez-Tamayo, R. 1978. Collagenase in experimental carbon tetrachloride cirrhosis of the liver. Am. J. Pathol. 92:411-420.
33. Arthur, M.J., Mann, D.A., and Iredale, J.P. 1998. Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. J. Gastroenterol. Hepatol. 13(Suppl.):S33-S38.
34. Brunt, E.M. 2004. Nonalcoholic steatoherpatits. Semin. Liver Dis. 24:3-20.
35. Ludwig, J., Viggiano, T.R., McGill, D.B., and Oh, B.J. 1980. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 55:434-438.
36. Sorensen, T.I., et al. 1984. Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet. 2:241-244.
37. Rockey, D.C. 2001. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin. Liver Dis. 21:337-349.
38. Milani, S., et al. 1990. Procollagen expression by nonparenchymal rat liver cells in experimental biliary fibrosis. Gastroenterology. 98:175-184.
39. Marra, F. 1999. Hepatic stellate cells and the regulation of liver inflammation. J. Hepatol. 31:1120-1130.
40. Olaso, E., et al. 2003. Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology. 37:674-685.
41. Friedman, S.L. 2000. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 275:2247-2250.
42. Bataller, R., et al. 2000. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 118:1149-1156.
43. Rockey, D.C. 2001. Cellular pathophysiology of portal hypertension and prospects for management with gene therapy. Clin. Liver Dis. 5:851-865.
44. Gressner, A.M., Weiskirchen, R., Breitkopf, K., and Dooley, S. 2002. Roles of TGF-beta in hepatic fibrosis. Front. Biosci. 7:d793-d807.
45. Pinzani, M., Gesualdo, L., Sabbah, G.M., and Abboud, H.E. 1989. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J. Clin. Invest. 84:1786-1793.
46. George, J., Roulot, D., Koteliansky, V.E., and Bissell, D.M. 1999. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc. Natl. Acad. Sci. U. S. A. 96:12719-12724.
47. Borkham-Kamphorst, E., Stoll, D., Gressner, A.M., and Weiskirchen, R. 2004. Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis. Biochem. Biophys. Res. Commun. 321:413-423.
48. Gao, R., and Brigstock, D.R. 2004. Connective tissue growth factor (CCN2) induces adhesion of rat activated hepatic stellate cells by binding of its C-terminal domain to integrin alpha(v)beta(3) and heparan sulfate proteoglycan. J. Biol. Chem. 279:8848-8855.
49. Williams, E.J., Gaca, M.D., Brigstock, D.R., Arthur, M.J., and Benyon, R.C. 2000. Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. J. Hepatol. 32:754-761.
50. Schuppan, D., Ruehl, M., Sonasundaram, R., and Hahn, E.G. 2001. Matrix as a modulator of hepatic fibrogenesis. Semin. Liver Dis. 21:351-372.
51. Gaca, M.D., et al. 2003. Basement membrane-like matrix inhibits proliferation and collagen synthesis by activated rat hepatic stellate cells: evidence for matrix-dependent deactivation of stellate cells. Matrix Biol. 22:229-239.
52. Zhou, X., et al. 2004. Engagement of alphavbeta3 integrin regulates proliferation and apoptosis of hepatic stellate cells. J. Biol. Chem. 279:23996-24006.
53. Olaso, E., et al. 2001. DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. J. Clin. Invest. 108:1369-1378. doi:10.1172/JCI200112373.
54. Friedman, S.L., Roll, F.J., Boyles, J., Arenson, D.M., and Bissell, D.M. 1989. Maintenance of differentiated phenotype of cultured rat hepatic lipocytes by basement membrane matrix. J. Biol. Chem. 264:10756-10762.
55. Zhou, X., et al. 2006. Impaired proteolysis of collagen I inhibits proliferation of hepatic stellate cells: Implication for regulation of liver fibrosis. J. Biol. Chem. 281:39757-39765.
56. Wells, R.G. 2005. The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J. Clin. Gastroenterol. 39(Suppl. 2):S158-S161.
57. Henderson, N.C., and Iredale, J.P. 2007. Liver fibrosis: cellular mechanisms of progression and resolution. Clin. Sci. 112:265-280.
58. Matsuoka, M., and Tsukamoto, H. 1990. Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor beta: implication for a pathogenetic role in alcoholic liver fibrogenesis. Hepatology. 11:599-605.
59. Friedman, S.L., and Arthur, M.J. 1989. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J. Clin. Invest. 84:1780-1785.
60. Ide, M., Kuwamura, M., Kotani, T., Sawamoto, O., and Yamate, J. 2005. Effects of gadolinium chloride (GdCl(3)) on the appearance of macrophage populations and fibrogenesis in thioacetamide-induced rat hepatic lesions. J. Comp. Pathol. 133:92-102.
61. Imamura, M., Ogawa, T., Sasaguri, Y., Chayama, K., and Ueno, H. 2005. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology. 128:138-146.
62. Duffield, J.S., et al. 2005. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Invest. 115:56-65. doi:10.1172/JCI200522675.
63. Radaeva, S., et al. 2006. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology. 130:435-452.
64. Jeong, W.I., Lee, C.S., Park, S.J., Chung, J.Y., and Jeong, K.S. 2002. Kinetics of macrophages, myofibroblasts and mast cells in carbon tetrachloride-induced rat liver cirrhosis. Anticancer Res. 22:869-877.
65. Li, C.Y., and Baek, J.Y. 2002. Mastocytosis and fibrosis: role of cytokines. Int. Arch. Allergy Immunol. 127:123-126.
66. Sugihara, A., Tsujimura, T., Fujita, Y., Nakata, Y., and Terada, N. 1999. Evaluation of role of mast cells in the development of liver fibrosis using mast cell-deficient rats and mice. J. Hepatol. 30:859-867.
67. Okazaki, T., et al. 1998. Increase of mast cells in the liver and lung may be associated with but not a cause of fibrosis: demonstration using mast cell-deficient Ws/Ws rats. Lab. Invest. 78:1431-1438.
68. Saito, J.M., Bostick, M.K., Campe, C.B., Xu, J., and Maher, J.J. 2003. Infiltrating neutrophils in bile duct-ligated livers do not promote hepatic fibrosis. Hepatol. Res. 25:180-191.
69. Xu, J., Lee, G., Wang, H., Vierling, J.M., and Maher, J.J. 2004. Limited role for CXC chemokines in the pathogenesis of alpha-naphthylisothiocyanate- induced liver injury. Am. J. Physiol. Gastrointest. Liver Physiol. 287:G734-G741.
70. Szpaderska, A.M., Egozi, E.I., Gamelli, R.L., and DiPietro, L.A. 2003. The effect of thrombocytopenia on dermal wound healing. J. Invest. Dermatol. 120:1130-1137.
71. Lesurtel, M., et al. 2006. Platelet-derived serotonin mediates liver regeneration. Science. 312:104-107.
72. Chambers, R.C., and Lurent, G.J. 2002. Coagulation cascade proteases and tissue fibrosis. Biochem. Soc. Trans. 30:194-200.
73. Wright, M., et al. 2003. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut. 52:1206-1210.
74. Safadi, R., et al. 2004. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology. 127:870-882.
75. Novobrantseva, T.I., et al. 2005. Attenuated liver fibrosis in the absence of B cells. J. Clin. Invest. 115:3072-3082. doi:10.1172/JCI24798.
76. Chiaramonte, M.G., Donaldson, D.D., Cheever, A.W., and Wynn, T.A. 1999. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J. Clin. Invest. 104:777-785.
77. Shi, Z., Wakil, A.E., and Rockey, D.C. 1997. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc. Natl. Acad. Sci. U. S. A. 94:10663-10668.
78. Canbay, A., et al. 2003. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab. Invest. 83:655-663.
79. Fadok, V.A., et al. 1998. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J. Clin. Invest. 101:890-898.
80. Paik, Y.H., et al. 2003. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology. 37:1043-1055.
81. Forbes, S.J., et al. 2004. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology. 126:955-963.
82. Russo, F.P., et al. 2006. The bone marrow functionally contributes to liver fibrosis. Gastroenterology. 130:1807-1821.
83. Kisseleva, T., et al. 2006. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J. Hepatol. 45:429-438.
84. Kinnman, N., and Housset, C. 2002. Peribiliary myofibroblasts in biliary type liver fibrosis. Front. Biosci. 7:496-503.
85. Knittel, T., et al. 1999. Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology. 117:1205-1221.
86. Ramadori, G., and Saile, B. 2002. Mesenchymal cells in the liver - one cell type or two? Liver. 22:283-294.
87. Cassiman, D., Libbrecht, L., Desmet, V., Denef, C., and Roskams, T. 2002. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J. Hepatol. 36:200-209.
88. Kalluri, R., and Neilson, E.G. 2003. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 112:1776-1784. doi:10.1172/JCI200320530.
89. Wells, R.G., Kruglov, E., and Dranoff, J.A. 2004. Autocrine release of TGF-beta by portal fiboblasts regulates cell growth. FEBS Lett. 559:107-110.
90. Alison, M.R., et al. 2000. Hepatocytes from non-hepatic adult stem cells. Nature. 406:257.
91. Alvarez-Dolado, M., et al. 2003. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature. 425:968-973.
92. Alison, M.R., et al. 2004. Hepatic stem cells: from inside and outside the liver? Cell Prolif. 37:1-21.
93. Magness, S.T., Bataller, R., Yang, L., and Brenner, D.A. 2004. A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology. 40:1151-1159.
94. Stefanovic, B., Hellerbrand, C., and Brenner, A. 1999. Regulatory role of the conserved stem-loop structure at the 5′ end of collagen alpha1(I)mRNA. Mol. Cell. Biol. 19:4334-4342.
95. Benyon, R.C., and Arthur, M.J. 2001. Extracellular matrix degradation and the role of hepatic stellate cells. Semin. Liver Dis. 21:373-384.
96. Vyas, S.K., Leyland, H., Gentry, J., and Arthur, M.J. 1995. Rat hepatic lipocytes synthesize and secrete transin (stromelysin) in early primary culture. Gastroenterology. 109:889-898.
97. Arthur, M.J., Friedman, S.L., Roll, F.J., and Bissell, D.M. 1989. Lipocytes from normal rat liver release aneutral metalloproteinase that degrades basement membrane (type IV) collagen. J. Clin. Invest. 84:1076-1085.
98. Arthur, M.J., et al. 1992. Secretion of 72 kDa type IV collagenase/gelatinase by cultured human lipocytes. Analysis of gene expression, protein synthesis and proteinase activity. Biochem. J. 287:701-707.
99. Benyon, R.C., Iredale, J.P., Goddard, S., Winwood, P.J., and Arthur, M.J. 1996. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology. 110:821-831.
100. Benyon, R.C., et al. 1999. Progelatinase A is produced and activated by rat hepatic stellate cells and promotes their proliferation. Hepatology. 30:977-986.
101. Zhou, X., et al. 2004. Expression of matrix metalloproteinase-2 and -14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis. Liver Int. 24:492-501.
102. Issa, R., et al. 2004. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology. 126:1795-1808.
103. Iredale, J.P., Murphy, G., Hembry, R.M., Friedman, S.L., and Arthur, M.J. 1992. Human hepatic lipcytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. J. Clin. Invest. 90:282-287.
104. Iredale, J.P., et al. 1998. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J. Clin. Invest. 102:538-549.
105. Issa, R., et al. 2001. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut. 48:548-557.
106. Elsharkawy, A.M., Oakley, F., and Mann, D.A. 2005. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis. 10:927-939.
107. Yoshiji, H., et al. 2000. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology. 32:1248-1254.
108. Yoshiji, H., et al. 2002. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology. 36:850-860.
109. Siller-Lopex, F., et al. 2004. Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology. 126:1122-1133.
110. Parsons, C.J., et al. 2004. Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology. 40:1106-1115.
111. Roeb, E., Behrmann, I., Grotzinger, J., Breuer, B., and Matern, S. 2000. An MMP-9 mutant without gelatinolytic activity as a novel TIMP-1 antagonist. FASEB J. 14:1671-1673.
112. Roderfeld, M., et al. 2006. Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J. 20:444-454.
113. Dienstag, J.L., et al. 2003. Histological outcome during long-term lamivudine therapy. Gastroenterology. 124:105-117.
114. Poynard, T., et al. 2002. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 122:1303-1313.
115. Hammel, P., et al. 2001. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N. Engl. J. Med. 344:418-423.
116. Desmet, V.J., and Roskams, T. 2004. Cirrhosis reversal: a duel between dogma and myth. J. Hepatol. 40:860-867.
117. Issa, R., et al. 2003. Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CC14-induced liver fibrosis, persistance of activated hepatic stellate cells and diminished hepatocyte regeneration. FASEB J. 17:47-49.
118. Preaux, A.M., D'ortho, M.P., Bralet, M.P., Laperche, Y., and Mavier, P. 2002. Apoptosis of human hepatic myofibroblasts promotes activation of matrix metalloproteinase-2. Hepatology. 36:615-622.
119. Friedman, S.L. 2000. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 275:2247-2250.
120. Ferru, I., Roye, O., Delacre, M., Auriault, C., and Wolowczuk, I. 1998. Infection of B-cell-deficient mice by the parasite Schistosoma mansoni: dominstration of the participation of B cells in granuloma modulation. Scand. J. Immunol. 48:233-240.